财务业绩表现 - 第三季度调整后每股收益为322美元 超出分析师预期的314美元 [1] - 第三季度营收同比增长13%至11亿美元 超过市场普遍预期的107亿美元 [1] - 第三季度有机营收增长达到12% [1] - 营业利润率扩大100个基点至321% [2] 业务板块驱动因素 - 伴侣动物群组部门收入增长14% 引领整体增长 [2] - CAG诊断经常性收入增长11% 有机增长为10% [2] - IDEXX VetLab耗材需求强劲 报告基础上增长18% [2] - 当季投放超过1700台IDEXX inVue Dx分析仪 [2] - CAG诊断资本仪器收入因此增长74% [2] 未来业绩指引 - 公司上调2025年全年营收指引至427亿美元至430亿美元 相当于增长96%至103% [3] - 同时上调每股收益指引至1281美元至1301美元 高于市场普遍预期的1263美元 [3]

IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) stock is trading higher on Monday after it reported better-than-expected third-quarter financial results and raised its 2025 forecast.The animal health company reported third-quarter 2025 adjusted earnings of $3.22 per share, up 15% year over year, beating the consensus of $3.13.The pet healthcare company reported sales of $1.105 billion, beating the consensus of $1.073 billion, up 13% on a reported and 12% on an organic basis, driven by Companion Animal Group (CAG) g ...